{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:14:19Z","timestamp":1789204459217,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.lungcan.2023.01.013","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T02:22:52Z","timestamp":1675218172000},"page":"87-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer"],"prefix":"10.1016","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9908-597X","authenticated-orcid":false,"given":"Ying","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsha","family":"Naicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah","family":"Shire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Gilberto","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2023.01.013_b0005","series-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","year":"2020"},{"issue":"10","key":"10.1016\/j.lungcan.2023.01.013_b0010","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jtho.2020.04.028","article-title":"Lung cancer in People's Republic of China","volume":"15","author":"Gao","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.01.013_b0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/1759-7714.12169","article-title":"Epidemiology of lung cancer in China","volume":"6","author":"Chen","year":"2015","journal-title":"Thorac Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2023.01.013_b0020","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1634\/theoncologist.2019-IO-S1-s02","article-title":"Retrospect and prospect for lung cancer in China: Clinical advances of Immune checkpoint inhibitors","volume":"24","author":"Lu","year":"2019","journal-title":"Oncologist"},{"issue":"22","key":"10.1016\/j.lungcan.2023.01.013_b0025","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"for the KEYNOTE-189 Investigators, Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10183","key":"10.1016\/j.lungcan.2023.01.013_b0030","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"KEYNOTE-042 investigators, pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.lungcan.2023.01.013_b0035","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"KEYNOTE-407 Investigators, pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.lungcan.2023.01.013_b0040","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.01.013_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.757993","article-title":"Immunotherapy in the first-line treatment of NSCLC: Current status and future directions in China","volume":"11","author":"Xiong","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.01.013_b0050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12885-020-6583-3","article-title":"Current status of the clinical use of PD-1\/PD-L1 inhibitors: a questionnaire survey of oncologists in China","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2023.01.013_b0055","unstructured":"AstraZeneca, Imfinzi approved in China for the treatment of unresectable, Stage III non-small cell lung cancer based on the Phase III PACIFIC trial. Press release December 12, 2019, https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/imfinzi-approved-in-china-for-the-treatment-of-unresectable-stage-iii-non-small-cell-lung-cancer-based-on-the-phase-iii-pacific-trial-12122019.html."},{"issue":"9","key":"10.1016\/j.lungcan.2023.01.013_b0060","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.lungcan.2023.01.013_b0065","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","article-title":"Immune checkpoint inhibitors of PD-L1 as cancer therapeutics","volume":"12","author":"Akinleye","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.01.013_b0070","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.lungcan.2023.01.013_b0075","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.lungcan.2023.01.013_b0080","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.01.013_b0085","unstructured":"AstraZeneca, Imfinzi approved in China for the treatment of extensive-stage small cell lung cancer. Press release July 19, 2021, https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2021\/imfinzi-approved-in-china-for-extensive-stage-sclc.html, 2021."},{"key":"10.1016\/j.lungcan.2023.01.013_b0090","unstructured":"L. Paz-Ares, M. Dvorkin, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, M.J. Hochmair, M. Ozguroglu, J.H. Ji, O. Voitko, A. Poltoratskiy, S. Ponce, F. Verderame, L. Havel, I. Bondarenko, A. Kazarnowicz, G. Losonczy, N.V. Conev, J. Armstrong, N. Byrne, N. Shire, H. Jiang, J.W. Goldman, C. investigators, Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial, Lancet 394(10212) (2019) 1929-1939."},{"issue":"10","key":"10.1016\/j.lungcan.2023.01.013_b0095","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1517\/14712598.8.10.1583","article-title":"Tremelimumab (CP-675,206): A fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers","volume":"8","author":"Tarhini","year":"2008","journal-title":"Expert Opin. Biol. Ther."},{"issue":"12","key":"10.1016\/j.lungcan.2023.01.013_b0100","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1158\/1078-0432.CCR-11-0407","article-title":"CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans","volume":"17","author":"Huang","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2023.01.013_b0105","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2019-9-2","article-title":"Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1\/PD-L1 therapies","volume":"9","author":"Puri","year":"2020","journal-title":"Drugs Context"},{"issue":"5","key":"10.1016\/j.lungcan.2023.01.013_b0110","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.annonc.2020.02.006","article-title":"ARCTIC: Durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer","volume":"31","author":"Planchard","year":"2020","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.01.013_b0115","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: The MYSTIC phase 3 randomized clinical trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2023.01.013_b0120","doi-asserted-by":"crossref","unstructured":"M.L. Johnson, B.C. Cho, A. Luft, J. Alatorre-Alexander, S.L. Geater, K. Laktionov, S.-W. Kim, G. Ursol, M. Hussein, F.L. Lim, C.-T. Yang, L.H. Araujo, H. Saito, N. Reinmuth, X. Shi, L. Poole, S. Peters, E.B. Garon, T. Mok, for the POSEIDON Investigators, Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: The phase III POSEIDON study, J Clin Oncol. Published online November 3, 2022. https:\/\/doi.org\/10.1200\/JCO.22.00975.","DOI":"10.1200\/JCO.22.00975"},{"key":"10.1016\/j.lungcan.2023.01.013_b0125","doi-asserted-by":"crossref","unstructured":"G. de Castro Jr, N. Rizvi, P. Schmid, K. Syrigos, C. Martin, N. Yamamoto, Y. Cheng, V. Moiseyenko, Y. Summers, I. Vynnychenko, S.Y. Lee, M. Bryl, A. Zer, M. Erman, C. Timcheva, R. Raja, K. Naicker, U. Scheuring, J. Walker, H. Mann, V. Chand, T. Mok, for the NEPTUNE Investigators, NEPTUNE: Phase III study of first-line durvalumab plus tremelimumab in patients with metastatic NSCLC, J Thorac Oncol. Published online October 11, 2022. https:\/\/doi.org\/10.1016\/j.jtho.2022.09.223.","DOI":"10.1016\/j.jtho.2022.09.223"},{"issue":"8","key":"10.1016\/j.lungcan.2023.01.013_b0130","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"issue":"21","key":"10.1016\/j.lungcan.2023.01.013_b0135","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2023.01.013_b0140","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.01.013_b0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/PPO.0000000000000301","article-title":"PD-L1 and emerging biomarkers in immune checkpoint blockade therapy","volume":"24","author":"Cottrell","year":"2018","journal-title":"Cancer J."},{"issue":"22","key":"10.1016\/j.lungcan.2023.01.013_b0150","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2023.01.013_b0155","article-title":"Pembrolizumab plus chemotherapy for Chinese patients with metastatic squamous NSCLC in KEYNOTE-407","volume":"2","author":"Cheng","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"issue":"9","key":"10.1016\/j.lungcan.2023.01.013_b0160","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/ijc.33399","article-title":"Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study","volume":"148","author":"Wu","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"13_Supplement","key":"10.1016\/j.lungcan.2023.01.013_b0165","doi-asserted-by":"crossref","first-page":"CT113","DOI":"10.1158\/1538-7445.AM2018-CT113","article-title":"Abstract CT113: Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC","volume":"78","author":"Chaft","year":"2018","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2023.01.013_b0170","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.01.013_b0175","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s10147-021-01899-8","article-title":"First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis","volume":"26","author":"Hotta","year":"2021","journal-title":"Int. J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223000430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223000430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:05:10Z","timestamp":1759237510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223000430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":35,"alternative-id":["S0169500223000430"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.01.013","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}